Related Experiment Videos

Percutaneous intervention for atherosclerotic disease in saphenous vein grafts

Niall T Mulvihill1, Jean Marco

  • 1Unite de Cardiologie Interventionnelle, Clinique Pasteur, 45 Avenue de Lombez, 31076, Toulouse, France. mulvihin@hotmail.com

International Journal of Cardiology
|May 15, 2002
PubMed

Insights

Coronary artery bypass surgery (CABG) benefits are limited by graft atherosclerosis. Percutaneous intervention is a preferred treatment for symptomatic saphenous vein graft (SVG) disease, with reviewed outcomes and advances.

Area of Science:

  • Cardiology
  • Vascular Surgery

Background:

  • Coronary artery bypass grafting (CABG) long-term efficacy is compromised by bypass conduit atherosclerosis.
  • Saphenous vein grafts (SVGs) are particularly prone to developing atherosclerotic disease, limiting CABG's durability.

Purpose of the Study:

  • To review the immediate and long-term outcomes of percutaneous intervention for atherosclerotic disease in saphenous vein grafts (SVGs).
  • To overview current therapeutic considerations and novel technical advancements in treating SVG atherosclerosis.

Main Methods:

  • Literature review of studies evaluating percutaneous intervention in SVG atherosclerotic disease.
  • Analysis of immediate and long-term results from percutaneous treatments.
  • Overview of therapeutic strategies and emerging technologies.

Main Results:

  • Percutaneous intervention is a common approach for symptomatic SVG atherosclerosis.
  • The review synthesizes data on the efficacy and limitations of current percutaneous techniques.
  • Novel advancements aim to improve long-term graft patency and patient outcomes.

Conclusions:

  • Percutaneous intervention offers a viable treatment option for SVG atherosclerotic disease.
  • Ongoing research and technological innovation are crucial for enhancing treatment effectiveness.
  • Optimizing SVG management is key to improving long-term CABG benefits.

Related Concept Videos